Impact of metabolic therapy on the state of cerebral hemodynamics in hypoestrogenemia

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To investigate the impact of therapy with Mildronate® on the state of cerebral hemodynamics, on vascular wall remodeling and endothelial dysfunction in women with hypertension and estradiol deficiency.

Subjects and methods. The investigation enrolled 37 patients (mean age, 43.0±3.5 years) with Stage I–II hypertension, reduced estradiol and elevated follicle-stimulating hormone (FSH) levels, who formed a study group. The patients in this group received Mildronate® in addition to standard therapy. A control group consisted of 38 healthy women (mean age 43.5±3.4 years) without chronic diseases affecting intracardiac and cerebral hemodynamics. Complete medical histories were taken from all the patients who underwent a mandatory laboratory test (including estradiol and FSH levels), ECG, and duplex scanning of the great cerebral arteries.

Results. The features of vascular bed remodeling, the state of cerebral hemodynamics, and endothelial dysfunction in the examinees can assume that hypoestrogenemia may be a factor contributing to the progression of hypertension and the development of complications, such as cerebrovascular accidents.

Conclusion. The study results have shown that Mildronate® is well tolerated by patients and is an effective treatment, showing a positive therapeutic effect on endothelium-dependent vascular relaxation, vascular remodeling, and whole-brain hemodynamics.

Full Text

Restricted Access

About the authors

M. Khabibulina

Ural State Medical University

Author for correspondence.
Email: m.xabibulina@mail.ru

Candidate of Medical Sciences

Russian Federation, Yekaterinburg

M. Shamilov

Ural State Medical University

Email: m.xabibulina@mail.ru
Russian Federation, Yekaterinburg

References

  1. Emelin A.Yu. Structural neuroimaging in the differential diagnostics of vascular cognitive impairment. Vestnik Rossiiskoi voenno-meditsinskoi akademii. 2010; 3: 97–102 (in Russ.).
  2. Suslina Z.A., Geraskina L.A., Fonyakin A.V. Arterial hypertension and stroke: communication and prevention prospects. Atmosfera. Kardiologiya. 2001; 1: 5–7 (in Russ.).
  3. Mashin V.V. Gipertonicheskaya entsefalopatiya: klinicheskie proyavleniya i tserebral'naya gemodinamika u bol'nykh s khronicheskoi serdechnoi nedostatochnost'yu. Avtoref. dis. ... kand. med. nauk. M., 2004 (in Russ.).
  4. Geraskina L.A. Khronicheskie tserebrovaskulyarnye zabolevaniya pri arterial'noi gipertonii: krovosnabzhenie mozga, tsentral'naya gemodinamika i funktsional'nyi sosudistyi rezerv. Avtoref. diss. … d-ra med. nauk. M., 2008 (in Russ.).
  5. Batalova A.A., Khovaeva Ya.B., Berg M.D. Etapnost' narusheniya endotelial'noi funktsii pri razvitii gipertonicheskoi bolezni i ateroskleroza. Cardiovascular Therapy and Prevention. 2008; 7 (6, S1): 44 (in Russ.).
  6. Nelidova A.V., Bunova S.S., Ostapenko V.A. Diagnosticheskie osobennosti rannego vyyavleniya disfunktsii endoteliya u bol'nykh gipertonicheskoi bolezn'yu. Cardiovascular Therapy and Prevention. 2008; 7 (6, S1): 262–3 (in Russ.).
  7. Kozlova M.V. Osobennosti narushenii mikrotsirkulyatsii u zhenshchin postmenopauzal'nogo perioda s arterial'noi gipertoniei. Avtoref dis. … kand. med. nauk. Ivanovo, 2008; 20 р. (in Russ.).
  8. Reckelhoff J.F. Gender differences in the regulation of blood pressure. Hypertension. 2001; 37 (5): 1199–208. doi: 10.1161/01.hyp.37.5.1199
  9. Khabibulina M.M. Left ventricular structure and geometry, peripheral artery endotheliumdependent vasodilatation, antihypertensive effect of ACE inhibitors, and hormone replacement therapy in premenopausal women with arterial hypertension. Cardiovascular Therapy and Prevention. 2011; 10 (2): 24–8 (in Russ.). doi: 10.15829/1728-8800-2011-2-24-28
  10. Khabibulina M.M. Structural and functional parameters of the vascular bed in premenopausal hypertensive women. Ter arkh. 2011; 83 (12): 11–5 (in Russ.).
  11. Khabibulina M.M. Effect of angiotensin converting enzyme lisinopril on the state of vascular bed in premenopausal women with arterial hypertension. Kardiologiia. 2013; 53 (2): 38–42 (in Russ.).
  12. Skornyakova M.N. Klinicheskie lektsii po ginekologicheskoi endokrinologii. Rukovodstvo dlya vrachei. Ekaterinburg, 2000; 384 р. (in Russ.).
  13. Karachentsev A.N., Sergeev P.V. Vasoactive effects of sex hormones. Problems of Endocrinology. 1997; 43 (2): 45–53 (in Russ.). doi: 10.14341/probl199743245-53
  14. Lyusov V.A., Evsikov E.M., Rudakov A.V. Rol' narushenii balansa polovykh gormonov i gonadotropinov v razvitii i techenii essentsial'noi gipertenzii u zhenshchin. Rossiiskii meditsinskii zhurnal. 1997; 3: 5–9 (in Russ.).
  15. Khabibulina M.M. Comparison of structural and geometric changes of the left heart, systolic and diastolic functions in women with hypertension in late fertile period and menopause. Cardiology & Cardiovascular Surgery. 2009; 2: 75–8 (in Russ.).
  16. Khabibulina M.M. Effect of hypoestrogenemia on quality of life of premenopausal women with arterial hypertension. Kardiologiia. 2013; 53 (11): 45–8 (in Russ.).
  17. Khabibulina M. The vascular bed in premenopausal women with arterial hypertension and dyslipidemia in estrogen deficiency. Vrach. 2013; 12: 31–6 (in Russ.).
  18. Khabibulina M.M. Kardiovaskulyarnyi risk pri estrogenodefitsite v doklimaktericheskikh periodakh. Ekaterinburg, 2014; 193 р. (in Russ.).
  19. Belova L.A., Mashin V.V., Gavrilyuk O.V. Autoregulyatsiya tserebral'noi gemodinamiki pri gipertonicheskoi entsefalopatii. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova (pril. «Insul't»). 2007; 214–5 (in Russ.).
  20. Stulin I.D. Osobennosti izucheniya venoznoi tserebral'noi tsirkulyatsii v norme i patologii. Sovremennye minimal'no-invazivnye tekhnologii (Neirokhirurgiya, vertebrologiya, nevrologiya, neirofiziologiya): Mat-ly VI mezhdunar. simpoziuma. SPb, 2001; р. 78–80 (in Russ.).
  21. Logina I.P., Kalvin'sh I.Ya. Mildronat v nevrologii. Riga, 2012; 54 р. (in Russ.).
  22. Maximova M.Yu., Fedorova T.N., Sharypova T.N. The use of mildronate in patients with cerebrovascular disease. Farmateka. 2013; 9: 84–94 (in Russ.).
  23. Maksimova M.Yu., Kistenev B.A., Domashenko M.A. et al. Clinical efficacy and antioxidant activity mildronata in ischemic stroke. Rus Cardiol J. 2009; 4 (78): 55–63 (in Russ.).
  24. Kravchuk E.N., Galagudza M.M. Experimental models of metabolic syndrome. Arterial Hypertension. 2014; 20 (5): 377–83 (in Russ.). doi: 10.18705/1607-419X-2014-20-5-377-383
  25. Kuzikov A.V., Bulko T.V., Masamrekh R.A. et al. Analysis of mildronate effect on the catalytic activity of cytochrome Р450 3А4. Vestnik RGMU. 2016; 6: 10–5 (in Russ.).
  26. Nikitin Yu.M. Novaya kontseptsiya strukturno- funktsional'nykh urovnei sosudistoi sistemy golovnogo mozga v otsenke ul'trazvukovoi diagnostiki. 13-ya Mezhdunar. konf. «Angiodop 2006». Sochi, 2006; р. 98–101 (in Russ.).
  27. Bokeriya L.A., Buziashvili Yu.I., Shumilina M.V. Narusheniya tserebral'nogo venoznogo krovoobrashcheniya u bol'nykh s serdechno sosudistoi patologiei (golovnaya bol', ishemiya, arterioskleroz). M.: Izd-vo NTsSSKh im. Bakuleva RAMN, 2003; 162 р. (in Russ.).
  28. Lelyuk V.G. Tserebral'noe krovosnabzhenie i arterial'noe davlenie. M.: Real'noe vremya, 2004; 304 р. (in Russ.).
  29. Preobrazhenskii D.V., Sidorenko B.A., Nosenko E.M. Brain as target organ in patients with hypertensive disease (essential hypertension). Kardiologiia. 2000; 1: 83–8 (in Russ.).
  30. Damulin I.V., Bryzhakhina V.G., Shashkova E.V. et al. Gait and balance disorders in patients with dyscirculatory encephalopathy. Part 2. Clinical-neuropsychological and MRI correlations. The Neurological Journal. 2004; 4: 13–8 (in Russ.).
  31. Schmidtke K., Hull М. Cerebral small vessel disease: how does it progress? J Neurol Sci. 2005; 229-230: 13–20. doi: 10.1016/j.jns.2004.11.048
  32. Roman С.С., Erkinjuntti Т. Subcortical ischemic vascular dementia. Lancet Neurol. 2002; 1 (7): 426–36. doi: 10.1016/s1474-4422(02)00190-4
  33. Larina V., Karpenko D. The metabolic and cytoprotective orientation of meldonium in multimorbidity. Vrach. 2022; 33 (4): 56–62 (in Russ.). doi: 10.29296/25877305-2022-04-08
  34. Shishkova V.N. Comorbidity and polypharmacy: focus on cytoprotection. Consilium Medicum. 2016; 18 (12): 73–9. (in Russ.). doi: 10.26442/2075-1753_2016.12.73-79
  35. Shishkova V., Kapustina L. A rational approach to solving cardiometabolic problems in the therapy of comorbid patients. Vrach. 2018; 29 (11): 3–11 (in Russ.). doi: 10.29296/25877305-2018-11-01
  36. Shishkova V., Remennik A., Kerimova E. et al. Evaluation of the efficiency of metabolic therapy in elderly patients with carbohydrate metabolism disorders after ischemic stroke. Vrach. 2020; 31 (3): 69–75 (in Russ.). doi: 10.29296/25877305-2020-03-15
  37. Shishkova V., Zotova L., Malyukova N. The possibility of enhancing the efficiency of early comprehensive rehabilitation in patients with poststroke aphasia. Vrach. 2018; 29 (6): 39–44 (in Russ.). doi: 10.29296/25877305-2018-06-08
  38. Allen C., Bayraktutan U. Oxidative stress and its role in the pathogenesis of ischaemic stroke. Int J Stroke. 2009; 4 (6): 461–70. doi: 10.1111/j.1747-4949.2009.00387.x
  39. Rumyantseva S.A., Stupin V.A. et al. Teoriya i praktika lecheniya bol'nykh s sosudistoi komorbidnost'yu. Klinicheskoe rukovodstvo. M., SPb: Mezhdunarodnaya izdatel'skaya gruppa «Med. kniga», 2013; 360 р. (in Russ.).
  40. Jaudzems K., Kuka J., Gutsaits A. et al. Inhibition of carnitineacetiltransferase by mildronate, a regulator of energy metabolism. J Enzime Inhib Med Chem. 2009; 24 (6): 1269–75. doi: 10.3109/14756360902829527
  41. Karpov R.S., Koshelskaya O.A., Vrublevsky A.V. et al. Clinical efficacy and safety of mildronate in patients with ischemic heart disease and chronic heart failure. Kardiologiia. 2000; 6: 69–74 (in Russ.).
  42. Nedoshivin A.O., Petrova N.N., Kutuzova A.E. et al. Effect of mildronate on life quality of patients with chronic heart failure. Ter Arkh. 1999; 71 (8): 10–2 (in Russ.).
  43. Dzerve V., Matisone D., Pozdnyakov Y. et al. Mildronate improves the exercise tolerance in patients with stable angina, results of a long term clinical trial. Semin Cardiovasc Med. 2010; 16: 8.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies